Cargando…

Fisetin in Cancer: Attributes, Developmental Aspects, and Nanotherapeutics

Cancer is one of the major causes of mortality, globally. Cancerous cells invade normal cells and metastasize to distant sites with the help of the lymphatic system. There are several mechanisms involved in the development and progression of cancer. Several treatment strategies including the use of...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Rachna M., Kumar, Hitesh, Bhatt, Tanvi, Jain, Rupshee, Panchal, Kanan, Chaurasiya, Akash, Jain, Vikas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9961076/
https://www.ncbi.nlm.nih.gov/pubmed/37259344
http://dx.doi.org/10.3390/ph16020196
_version_ 1784895665963270144
author Kumar, Rachna M.
Kumar, Hitesh
Bhatt, Tanvi
Jain, Rupshee
Panchal, Kanan
Chaurasiya, Akash
Jain, Vikas
author_facet Kumar, Rachna M.
Kumar, Hitesh
Bhatt, Tanvi
Jain, Rupshee
Panchal, Kanan
Chaurasiya, Akash
Jain, Vikas
author_sort Kumar, Rachna M.
collection PubMed
description Cancer is one of the major causes of mortality, globally. Cancerous cells invade normal cells and metastasize to distant sites with the help of the lymphatic system. There are several mechanisms involved in the development and progression of cancer. Several treatment strategies including the use of phytoconstituents have evolved and been practiced for better therapeutic outcomes against cancer. Fisetin is one such naturally derived flavone that offers numerous pharmacological benefits, i.e., antioxidant, anti-inflammatory, antiangiogenic, and anticancer properties. It inhibits the rapid growth, invasiveness, and metastasis of tumors by hindering the multiplication of cancer cells, and prompts apoptosis by avoiding cell division related to actuation of caspase-9 and caspase-8. However, its poor bioavailability associated with its extreme hydrophobicity hampers its clinical utility. The issues related to fisetin delivery can be addressed by adapting to the developmental aspects of nanomedicines, such as formulating it into lipid or polymer-based systems, including nanocochleates and liposomes. This review aims to provide in-depth information regarding fisetin as a potential candidate for anticancer therapy, its properties and various formulation strategies.
format Online
Article
Text
id pubmed-9961076
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99610762023-02-26 Fisetin in Cancer: Attributes, Developmental Aspects, and Nanotherapeutics Kumar, Rachna M. Kumar, Hitesh Bhatt, Tanvi Jain, Rupshee Panchal, Kanan Chaurasiya, Akash Jain, Vikas Pharmaceuticals (Basel) Review Cancer is one of the major causes of mortality, globally. Cancerous cells invade normal cells and metastasize to distant sites with the help of the lymphatic system. There are several mechanisms involved in the development and progression of cancer. Several treatment strategies including the use of phytoconstituents have evolved and been practiced for better therapeutic outcomes against cancer. Fisetin is one such naturally derived flavone that offers numerous pharmacological benefits, i.e., antioxidant, anti-inflammatory, antiangiogenic, and anticancer properties. It inhibits the rapid growth, invasiveness, and metastasis of tumors by hindering the multiplication of cancer cells, and prompts apoptosis by avoiding cell division related to actuation of caspase-9 and caspase-8. However, its poor bioavailability associated with its extreme hydrophobicity hampers its clinical utility. The issues related to fisetin delivery can be addressed by adapting to the developmental aspects of nanomedicines, such as formulating it into lipid or polymer-based systems, including nanocochleates and liposomes. This review aims to provide in-depth information regarding fisetin as a potential candidate for anticancer therapy, its properties and various formulation strategies. MDPI 2023-01-28 /pmc/articles/PMC9961076/ /pubmed/37259344 http://dx.doi.org/10.3390/ph16020196 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Kumar, Rachna M.
Kumar, Hitesh
Bhatt, Tanvi
Jain, Rupshee
Panchal, Kanan
Chaurasiya, Akash
Jain, Vikas
Fisetin in Cancer: Attributes, Developmental Aspects, and Nanotherapeutics
title Fisetin in Cancer: Attributes, Developmental Aspects, and Nanotherapeutics
title_full Fisetin in Cancer: Attributes, Developmental Aspects, and Nanotherapeutics
title_fullStr Fisetin in Cancer: Attributes, Developmental Aspects, and Nanotherapeutics
title_full_unstemmed Fisetin in Cancer: Attributes, Developmental Aspects, and Nanotherapeutics
title_short Fisetin in Cancer: Attributes, Developmental Aspects, and Nanotherapeutics
title_sort fisetin in cancer: attributes, developmental aspects, and nanotherapeutics
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9961076/
https://www.ncbi.nlm.nih.gov/pubmed/37259344
http://dx.doi.org/10.3390/ph16020196
work_keys_str_mv AT kumarrachnam fisetinincancerattributesdevelopmentalaspectsandnanotherapeutics
AT kumarhitesh fisetinincancerattributesdevelopmentalaspectsandnanotherapeutics
AT bhatttanvi fisetinincancerattributesdevelopmentalaspectsandnanotherapeutics
AT jainrupshee fisetinincancerattributesdevelopmentalaspectsandnanotherapeutics
AT panchalkanan fisetinincancerattributesdevelopmentalaspectsandnanotherapeutics
AT chaurasiyaakash fisetinincancerattributesdevelopmentalaspectsandnanotherapeutics
AT jainvikas fisetinincancerattributesdevelopmentalaspectsandnanotherapeutics